The role of chemotherapy in the management of Nasopharyngeal carcinoma

Cancer

Volumn 82, Issue 6, 1998, Pages 1003-1012

  Chan, Anthony T C ^a   Teo, Peter M L ^a   Leung, Thomas W T ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adjuvant; Chemotheraphy; Concurrent; Nasopharyngeal carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN C;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 0032520781     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1003::AID-CNCR1>3.0.CO;2-F     Document Type: Article

References (88)

1. Hong Kong Cancer Registry 1991 Annual Statistical Report. Hong Kong: Hospital Authority, July 1995.
2. Lee AWM, Poon YF, Foo W, Law SCK, Cheung FK, Chan DKK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
3. Ho JHC. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978;4:183-205.
4. World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
5. Yu MC, Ho JHC, Lai SH, Henderson BE. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res 1986;46: 956-61.
6. Zur Hausen H, Schulte-Holthausen H, Klein G. Epstein-Barr virus DNA in biopsies of Burkitt tumors and anaplastic carcinoma of the nasopharynx. Nature 1970;228:1056-9.
7. De-Vathaire F, Sancho-Garnier H, De-The H. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer 1984;33:777-82.
8. Chan SH, Day HE, Kunaratnam N, Chia KB, Simons MJ. HLA and nasopharyngeal carcinoma in Chinese: a further study. Int J Cancer 1983;32:171-6.
9. Porter MJ, Field JK, Lee JCK, Leung SF, Lo D, van Hasselt CA. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Cancer Res 1994;14:1357-60.
10. Lo KW, Tsao SY, Leung SF, Choi PHK, Lee JCK, Huang DP. Detailed deletion mapping on the short arm of chromosome 3 in nasopharyngeal carcinomas. Int J Oncol 1994;4:1359-64.
11. Huang DP, Lo KW, van Hasselt CA, Woo JKS, Choi PHK, Leung SF, et al. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 1994;54:4003-6.
12. Krueger GR, Kottaridis SD, Wolf H, Ablashi DV, Sesterhenn K, Bertram G. Histological types of nasopharyngeal carcinoma as compared to EBV serology. Anticancer Res 1981;1: 187-94.
13. Pearson GR, Weiland LH, Neel HB, Taylor W, Earle J, Mulroney SE, et al. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983;51:260-8.
14. Neel HB, Taylor WF. New staging system for nasopharyngeal carcinoma: long-term outcome. Arch Otolaryngol Head Neck Surg 1989;115:1293-1303.
15. Shammugaratnam K, Chan SH, de The G, Goh JEH, Khor TH, Simons MJ, et al. Histopathology of nasopharyngeal carcinoma: correlations with epidemiology, survival rates, and other biologic characteristics. Cancer 1979;44:1029-44.
16. Hoppe R, Goffinet D, Bagshaw M. Carcinoma of the nasopharynx: eighteen years' experience with megavoltage radiation therapy. Cancer 1976;37:2605-17.
17. Marks JE, Bedwinek JM, Lee F, Purdy JA, Perez CA. Dose response analysis for nasopharyngeal carcinoma. Cancer 1982;50:1042-50.
18. Qin D, Hu Y, Yan J, Xu G, Cai W, Wu X, et al. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 1988;61:1117-24.
19. Wang CC, Meyer JE. Radiotherapeutic management of carcinoma of the nasopharynx: analysis of 170 patients. Cancer 1971;28:566-70.
20. Ho JHC. Stage classification of nasopharyngeal carcinoma: a review. In: de Tha G, Ito Y, editors. Nasopharyngeal carcinoma: etiology and control. Lyon, France: IARC Scientific Publications, 1978;99-113.
21. Teo PML, Tsao SY, Ho JHC, Yu P. A proposed modification of the Ho stage-classification for nasopharyngeal carcinoma. Radiother Oncol 1991;21:11-23.
22. Sham JST, Choy D. Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. Br J Radiol 1989;63:51-8.
23. American Joint Committee for Cancer Staging and End Results. Manual for staging of cancer. Chicago: The American Joint Committee, 1980.
24. Harmer MN. TNM classification of malignant tumors. 3rd edition. Geneva: Union Internationale contre le Cancer, 1978;27-32.
25. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol 1986; 33:184-97.
26. Teo P, Leung SF, Yu P, Lee WY, Shiu W. A retrospective comparison between different stage classifications for nasopharyngeal carcinoma. Br J Radiol 1991;64:901-8.
27. Teo PML, Tsao SY, Shiu W, Leung WT, Tsang V, Yu P, et al. A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong. Int J Radiat Oncol Biol Phys 1989;17:515-30.
28. Teo P, Shiu W, Leung SF, Lee WY. Prognostic factors in nasopharyngeal carcinoma investigated by computer tomography: an analysis of 659 patients. Radiother Oncol 1992; 23:79-93.
29. Decker DA, Drelichman A, Al-Sarraf M. Chemotherapy for nasopharyngeal carcinoma: a ten-year experience. Cancer 1983;52:602-5.
30. Al Kourainy K, Crissman C, Ensley J, Kish J, Kelly J, Al-Sarraf M. Excellent response to cisplatin-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol 1988;11:427-30.
31. Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx: a review of the Princess Margaret Hospital experience. Cancer 1991;68:2120-4.
32. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol 1988;15:70-85.
33. Cripps C, Odell P, Danjoux C, Nichol J, Bastide Y, Barron P, et al. Pretreatment with chemotherapy in patients with advanced head and neck cancer. J Otolaryngol 1985;14:391-3.
34. Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1987;5:10-20.
35. Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE, et al. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. Cancer 1987; 60:1178-83.
36. Jacobs JR, Pajak TF, Kinzie J, Al-Sarraf M, Davis L, Hanks GA, et al. Induction chemotherapy in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1987;113: 193-7.
37. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Cancer 1987;60:301-11.
38. Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metast Rev 1987;6:191-8.
39. Al-Sarraf M. Management strategies in head and neck cancer: the role of carboplatin. In: Bunns PA Jr., Canetta R, Ozols RF, Rozencqeig M, editors. Carboplatin (JM-8): current perspectives and future directions. Philadelphia: W. B. Saunders, 1990.
40. Shiu WCT, Tsao SY. Efficacy of 4′-epidoxorubicin (Pharmorubicin) in advanced nasopharyngeal carcinoma. Clinical Trials Journal 1989;26:419.
41. Dugan M, Choy D, Ngai A, Sham J, Choi P, Shiu W, et al. Multicenter Phase II trial of mitozantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanic Clinical Oncology Association Group study. J Clin Oncol 1993;11:70.
42. Au E, Ang PT, Chuen EJ. Paclitaxel in metastatic nasopharyngeal cancer [abstract]. Proc ASCO 1996;15:919.
43. Bernal AG, Cruz JJ, Sanchez P, Munoz A, Nieto A, Fonseca E, et al. Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. Cancer 1989;63:1927-30.
44. Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982;66:471-4.
45. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
46. Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer 1994;73:2:247-52.
47. Su WC, Chen TY, Kao RH, Tsao CJ. Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology 50:205-8.
48. Boussen H, Cvitkovic E, Wendling JL, Bachouchi M, Mahjoubi R, Kalifa C. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 1991;9: 1675-81.
49. Mahjoubi R, Azli N, Bachouchi M, Soulie P, Wibault P. Metastatic undifferentiated carcinoma of nasopharyngeal type treated with bleomycin (B), epirubicin (E) and cisplatin (C): final report [abstract 772]. Proc ASCO 1992;11:240.
50. Cvitkovic E, Mahjoubi R, Lianes P, Armand JP, Azli N, Wibault P. 5-Fluorouracil (FU), mitomycin (M), epirubicin (E), cisplatin (P) in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma (UCNT) [abstract 664]. Proc ASCO 1991;10:200.
51. Altun M, Fandi A, Dupos O, Cvitkovic E, Krajina Z, Eschuege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995;32:859-77.
52. Taamma A, Fandi A, Azli N, Bachouchi M, Couteau C. 5 Fluorouracil (FU) bleomycin (B), epirubicin (E), cisplatin (P) in locally advanced (LA), recurrent and/or metastatic (REC/ MTS) undifferentiated carcinoma nasopharyngeal type (UCNT) preliminary activity/toxicity report. Proc ASCO 1996;15:909.
53. Tannock IF. Chemotherapy for nasopharyngeal cancer: the CAPABLE regimen (cyclophosphamide, doxorubicin, cisplatin, methotrexate and bleomycin). Proc ASCO 1996;15: 916.
54. Yeo W, Leung TWT, Leung SF, Teo PML, Chan ATC, Lee WY, et al. Phase II study of combination carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 1996;38:466-70.
55. Teo PML, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996;77: 2423-31.
56. Cvitkovic E, Bachouchi M, Armand JP. Nasopharyngeal carcinoma: biology, natural history, and therapeutic implications. Hematol Oncol Clin North Am 1991;5:821-38.
57. Atichartakarn V, Kraiphibul P, Clongsusuek P, Pochanugool L, Kulapaditharom B, Ratanatharathorn V. Nasopharyngeal carcinoma: result of treatment with cis-diamminedichloroplatinum II, 5 fluorouracil, and radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:461-9.
58. Bachouchi M, Cvitkovic E, Azli N, Gasmi J, Cortes-Funes H, Houssen H. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst 1990;82:616-20.
59. Clark JR, Norris CM, Dreyfuss AI, Fallon BG, Balogh K, Anderson RF. Nasopharyngeal carcinoma: the Dana-Farber Cancer Institute experience with 24 patients treated with induction chemotherapy and radiotherapy. Ann Otol Rhinol Laryngol 1987;96:608-14.
60. Dimery IW, Peters LJ, Goepfert H, Morrisone WH, Byers RM, Guillory C. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 1993;11:1919-28.
61. Galligioni E, Carbone A, Tirelli U, Veronesi A, Trovo MG, Magri MD. Combined chemotherapy with doxorubicin, bleomycin, vinblastine, dacarbazine, and radiotherapy for advanced lymphoepithelioma. Cancer Treat Rep 1982;66: 1207-10.
62. Tannock I, Payne D, Cummings B, Hewitt K, Panzarella T. Sequential chemotherapy and radiation for nasopharyngeal cancer: absence of long-term benefit despite a high rate of tumor response to chemotherapy. J Clin Oncol 1987;5: 629-34.
63. International Nasopharynx Cancer Study Group: VUMCAI Trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥N2,M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996;35:463-9.
64. Teo PML, Leung TWT, Chan ATC, Yu P, Lee WY, Leung SF, et al. A retrospective study of the use of cisplatinum-5-fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC). Oral Oncol Eur J Cancer 1995;31B:6:373-9.
65. Rossi A, Molinari R, Boracchi P, Vecchio MD, Marubini E, Nava M. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-10.
66. Dimery IW, Legha SS, Peters LJ, Goepfert H, Oswald MJ. Adjuvant chemotherapy for advanced nasopharyngeal carcinoma. Cancer 1987;60:943-9.
67. Khoury GG, Paterson ICM. Nasopharyngeal carcinoma: a review of cases treated by radiotherapy and chemotherapy. Clin Radiol 1987;38:17-20.
68. Rahima M, Rakowsky E, Barzilay J, Sidi J. Carcinoma of the nasopharynx: an analysis of 91 cases and a comparison of differing treatment approaches. Cancer 1986;58:843-9.
69. Tsujii H, Kamada T, Tsuji H, Takamura A, Matsuoka Y, Usubuchi H. Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy. Cancer 1989;63:1668-72.
70. Chan ATC, Teo PML, Leung WT, Leung SF, Lee WY, Yeo W, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33: 3:569-77.
71. Fu KK, Phillips TL, Silverger IJ, Jacobs C, Goffinet DR, Chun C. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-8.
72. Lo TCM, Wiley AL, Ansfield FJ, Brandenburg JH, Davis HL, Gollin FF. Combined radiation and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol 1976;126: 229-35.
73. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer. Laryngoscope 1988;98:1205-11.
74. Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989;17:3-9.
75. Turner SL, Tiver KW. Synchronous radiotherapy and chemotherapy in the treatment of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1993;27:371-7.
76. Souhami L, Rabinowits M. Combined treatment in carcinoma of the nasopharynx. Laryngoscope 1988;98:881-3.
77. Forastiere AA. Cisplatin and radiotherapy in the management of locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1993;27:465-70.
78. Forastiere AA. Concurrent cisplatinum and radiation for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1995;31:679-80.
79. Dewitt L. Combined treatment of radiation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987;13:403-26.
80. Kallman RF. The importance of schedule and drug dose intensity in combinations of modalities. Int J Radiat Oncol Biol Phys 1994;28:761-71.
81. Schwachofer JHM, Crooijmans RPNM, Hoogenhout J, Kal HB, Theeuwes AGM. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys 1991;20:1235-41.
82. Glicksman AS, Slotman G, Doolittle C, Clark J, Koness J, Coachman N. Concurrent cisplatinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1994;30:1043-50.
83. Bachaud JM, David JM, Boussin G, Daly N. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys 1991;20:243-6.
84. Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, Al-Sarraf M, Mowry PA. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer 1990;66:1861-8.
85. Al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group study. J Clin Oncol 1990;8:1342-51.
86. Al-Sarraf M, LeBlanc M, Giri PGS, Fu K, Cooper J, Vuong T, et al. Superiority of chemo-radiotherapy vs. radiotherapy in patients with locally advanced nasopharyngeal cancer: preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc ASCO 1996;15:882.
87. Al-Sarraf M, McLanglin PW. Nasopharynx carcinoma: choice of treatment. Int J Radiat Oncol Biol Phys 1995;33:3:761-3.
88. Teo P, Leung SF, Yu P, Tsao SY, Foo W, Shiu W. Comparison of the Ho's, UICC and AJCC stage classification for nasopharyngeal carcinoma (NPC). Cancer 1991;67:434-9.